1.Lim A, Verrier T, Vosshenrich C, Di Santo J. Developmental options and functional plasticity of innate lymphoid cells. Curr Opin Immunol. 2017;44:61–68. PMID: 28359987 Reference Link
1.Tang Y, Kang Y. Microbial metabolite as icebreaker for immunotherapy. Cell Metab. 2022;34(4):506–507. PMID: 35385701 Reference Link
1.Pérez-Núñez I, Rozalén C, Palomeque J, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu D, Shen M, Berenguer J, Ruiz I, Peña R, Montañés J, Albà M, Bonnin S, Ponomarenko J, Gomis R, Cejalvo J, Servitja S, Marzese D, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. Nat Cancer. 2022;3(3):355–370. PMCID: 5391692 Reference Link
1.Esposito M, Ganesan S, Kang Y. Emerging strategies for treating metastasis. Nat Cancer. 2021;2(3):258–270. PMCID: PMC8064405 Reference Link
1.Aiello-Couzo N, Kang Y. A bridge between melanoma cell states. Nat Cell Biol. 2020;22(8):913–914. PMID: 32753670 Reference Link
1.Zhang Y, Kurupati R, Liu L, Zhou X, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis G, Schuchter L, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman G, Rabinowitz J, Ertl H. Enhancing CD8 T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 2017;32(3):377–391.e9. PMCID: PMC5751418 Reference Link
1.Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 2016;161:79–96. PMCID: PMC4851893 Reference Link
